AboutUs
News
Career
Donate
Contact

MEDICAL WOMEN'S HEALTH

The focus of this department is clinical and translational research specific to health issues important for the care of women. Currently, the department is working in conjuction with the Biomedical Laboratories for Integrative Cancer Research (BLICaR) at the College of Staten Island, City University of New York to develop new methods to improve cervical cancer screening. A novel staining method for the diagnosis of cervical cancer and pre-cancerous lesions has been developed and has led to the filing of a patent with Staten Island University Hospital as the sponsoring institution.

Division Director
Mario Castellanos, MD - Director of Clinical Research

Grants, Patent Filing, Presentations and Publications

Recent Grants

  • Empire Clinical Research Investigator Program
    2009-2011
    New York State Department of Health
    "Abnormal Pap Smear Management"
    PI: M. Castellanos, MD
    Award: $150,000
  • Empire Clinical Research Investigator Program
    2008- 2009
    New York State Department of Health
    "Effects of pre-admission glucose control reflected by HgA1C levels on the morbidity and mortality of patients admitted to the ICU."
    PI: M. Castellanos, MD
    Award: $75,000

International Patent Filing

  • Title: A histochemical method to identify and predict disease progression of Human Papilloma Virus-infected lesions
    Inventor: Mario Castellanos, MD
    Application Assignment: SIUH and the Feinstein Institute for Medical Research International application No:PCT/US 09/49539 (WO/2010/003072)
    Filing date: July 2, 2009
    Publication: World Intellectual Property Organization: http://www.wipo.int/pctdb/en/

Invited Presentations

  • Castellanos M. The development of a novel curcumin-based vaginal cream vacurin which selectively eliminates cervical cancer cells. 26th international papillomavirus conference and workshops. San Juan Puerto Rico 11/12.
  • Abdallah, M, Choueiry, S, Mehta, C, Saifan, CNasr, R, El Sayegh, S. Alport’s syndrome in pregnancy. Accepted for poster presentation NYACP Albany on 5/25/12
  • LEEP versus cryotherapy: rates of HPV detection after treatment for CIN II/III. - American Society of Colposcopy and Cervical Pathology 2012 Biennial Scientific Meeting. March 2012, San Francisco, CA.

  • LEEP versus cryotherapy: rates of HPV detection after treatment for CIN II/III. - American Society of Colposcopy and Cervical Pathology 2012 Biennial Scientific Meeting. March 2012, San Francisco, CA.

  • Endonuclease resistant DNA: A new marker to identify and predict disease progression of Human Papilloma Virus-infected lesions. - 26th International Papillomavirus Conference and Workshops. July 2010, Montréal, Canada.

  • Virion associated DNA: A novel histochemical marker to identify women that are at risk to develop precancerous lesions of the cervix. - Society of Gynecologic Oncology 41 st Annual Meeting. March 2010, San Francisco, CA.

  • Endonuclease Resistant DNA: A novel histochemical biomarker to distinguish low from high grade cervical intraepithelial neoplasia. - American Society of Colposcopy and Cervical Pathologists. March 2010, Las Vegas, NV.

Publications

© 2013 Staten Island University Hospital. All Rights Reserved.

Privacy Policy | Sitemap | Notice of Privacy Practices | Compliance & Patient Privacy | Disclaimer